HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme
Help Login Register
Market News Stocks News ETF News Crypto News

Outlook Therapeutics, Inc.

Contributing Author

Recent Articles by Outlook Therapeutics, Inc.

Jul-01
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer OTLK GlobeNewswire
Jun-18
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event OTLK GlobeNewswire
Jun-10
Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD OTLK GlobeNewswire
Jun-02
Outlook Therapeutics Announces Commercial Launch of LYTENAVA (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD OTLK GlobeNewswire
May-23
Outlook Therapeutics Announces Pricing of $13.0 Million Public Offering OTLK GlobeNewswire
May-22
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants OTLK GlobeNewswire
May-15
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update OTLK GlobeNewswire
Affiliate • Advertise • Theme Settings • Contact • Help • Privacy • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

Learn more about FINVIZ*Elite